Phase 2 Start
GHRS: Phase2_Start: The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKD
October 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2026
- Company
- GH Research PLC (GHRS)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start
Phase2_Start: The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKD
- Company
- GH Research PLC (GHRS)
Other upcoming events for GHRS
Phase 3 StartPhase3_Start: A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator's Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Phase 3 StartPhase3_Start: A Multicentre, Prospective, Randomized, Open-label, Blinded Endpoint, Clinical Trial Evaluating Subcutaneous Semaglutide in Patients With Acute Ischaemic Stroke Due to Anterior Circulation Large Vessel Occlusion Treated With Endovascular Thrombectomy
Phase 3 StartPhase3_Start: A Double-blind, Randomized, Placebo-controlled, Phase III Study for Reducing Dependency and Cardiovascular Events With Oral Colchicine 0.5mg Once Daily Compared With Placebo in Participants With Spontaneous Intracerebral Hemorrhage and Established, or Risk Factors for, Atherosclerosis
Phase 1 StartPhase1_Start: Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma (PRECISE)
Phase 2 StartPhase2_Start: A Randomized Trial of Omega-3 Dietary Supplementation, Anti Demodex Eyelid Cleanser, and Standard Eyelid Cleanser for Pediatric Chalazia